IRF1 Antibody

What is IRF1 and why is it important in immunological research?

IRF1 (Interferon Regulatory Factor 1) is a 325 amino acid protein transcription factor that plays critical roles in immune regulation. It functions as a transcriptional activator for type I interferon genes and displays remarkable functional diversity in regulating cellular responses. IRF1 is crucial for antiviral defense, immune regulation, tumor immune surveillance, and the development of the immune system. Research has demonstrated that IRF1 promotes innate immune responses to viral infections by enhancing IRF3 activation and blocking the interaction between IRF3 and protein phosphatase 2A (PP2A) . This mechanism contributes to its central role in upregulating innate immunity against viral pathogens.

How should I select the appropriate IRF1 antibody for my specific experimental applications?

Selection of an appropriate IRF1 antibody depends on several factors:

When selecting an antibody, verify the species reactivity (human, mouse, or rat) matches your experimental model. Also confirm the antibody has been validated for your specific application through published literature or manufacturer validation data. For challenging applications like ChIP or Co-IP, choose antibodies specifically validated for these techniques .

What are the optimal conditions for detecting IRF1 in Western blot experiments?

Optimal Western blot conditions for IRF1 detection include:

• Sample preparation: IRF1 expression can be enhanced by treating cells with IFN-gamma. Use IFN-gamma-treated HeLa, HL-60, or THP-1 cells as positive controls .

• Protein amount: Load 20-40 μg of total protein per lane for standard cell lysates.

• Antibody dilution: Use primary IRF1 antibody at 1:500-1:1000 dilution .

• Detection: Expect bands at 45-50 kDa, not at the calculated 37 kDa .

• Controls: Include both positive (IFN-gamma treated cells) and negative controls (IRF1 knockout cells if available).

For optimizing signal-to-noise ratio, it is recommended to titrate both primary and secondary antibodies and to include appropriate blocking reagents to minimize background.

How can I optimize immunofluorescence detection of IRF1 protein?

For optimal immunofluorescence detection of IRF1:

• Cell preparation: Use IFN-gamma treated cells (e.g., HepG2 cells) as positive controls .

• Fixation: 4% paraformaldehyde for 15 minutes at room temperature works well for IRF1 detection.

• Permeabilization: 0.1-0.3% Triton X-100 in PBS for 10 minutes.

• Blocking: 5% normal serum (matching secondary antibody host) with 1% BSA for 1 hour.

• Primary antibody: Use IRF1 antibody at 1:50-1:500 dilution . Incubate overnight at 4°C or 2 hours at room temperature.

• Secondary antibody: Use appropriate fluorophore-conjugated secondary or directly conjugated primary antibodies such as CoraLite® Plus 488-conjugated IRF1 antibody .

• Nuclear counterstain: DAPI is recommended as IRF1 shows nuclear localization upon activation.

• Imaging: Look for both nuclear and cytoplasmic signals as IRF1 can be found in both compartments .

What are the best practices for using IRF1 antibodies in flow cytometry?

Best practices for IRF1 flow cytometry include:

• Cell preparation: Single-cell suspensions with >95% viability are crucial.

• Controls: Include unstained, isotype, and positive controls (e.g., Jurkat cells) .

• Fixation/Permeabilization: Since IRF1 is primarily intracellular, use fixation/permeabilization buffers compatible with nuclear transcription factor staining.

• Antibody amount: For intracellular staining, use 0.40-0.50 μg antibody per 10^6 cells in 100 μl suspension .

• Incubation: 30-45 minutes at room temperature in the dark.

• Washing: Multiple gentle washes to reduce background.

• Data analysis: Set appropriate gating strategies based on controls.

For multicolor panels, select fluorophores with minimal spectral overlap with your IRF1 antibody conjugate, particularly when using the CoraLite® Plus 488 conjugate which has excitation/emission maxima at 493/522 nm .

How does IRF1 expression change in response to interferon stimulation, and how can this be effectively measured?

IRF1 is strongly induced by type I and II interferons through the JAK/STAT signaling pathway. The dynamics of IRF1 expression follow a time-dependent pattern:

• Basal expression: Low in most unstimulated cells

• Early induction: Detectable at 2-4 hours post-IFN stimulation

• Peak expression: 6-12 hours post-stimulation

• Resolution: Decreases by 24 hours due to protein degradation

To effectively measure these changes:

• Time course experiments: Sample cells at multiple timepoints (0, 2, 4, 8, 12, 24 hours) after IFN stimulation.

• Western blot: Quantitatively assess protein levels using validated IRF1 antibodies .

• qRT-PCR: Complement protein analysis with mRNA quantification.

• Flow cytometry: For heterogeneous populations, use intracellular staining with an IRF1 antibody to examine cell-specific responses .

• Immunofluorescence: To visualize subcellular localization changes (cytoplasmic to nuclear) upon activation .

Validation experiments should include appropriate controls such as IFN-gamma treated HeLa, HepG2, or THP-1 cells as positive controls .

What are the methodological approaches to study IRF1's role in the antitumor immune response?

To study IRF1's role in antitumor immunity, researchers can employ several methodological approaches:

• Tumor cell IRF1 manipulation:

  • Generate IRF1 knockout tumor cell lines using CRISPR/Cas9

  • Create IRF1 overexpressing tumor cell lines

  • Compare tumor growth and immune infiltration in wild-type vs. IRF1-modified tumors

• Immune checkpoint blockade studies:

  • Evaluate anti-PD-1 and anti-CTLA-4 responses in IRF1-positive vs. IRF1-negative tumors

  • Research shows that IRF1-negative tumors may respond better to immune checkpoint blockade therapy

• Analysis of IRF1-regulated pathways:

  • Examine IRF1-induced PD-L1 expression through KAT8-IRF1 biomolecular condensate formation

  • Use peptide inhibitors (like 2142-R8) to disrupt KAT8-IRF1 condensates and analyze effects on PD-L1 expression and antitumor immunity

• Methodological considerations:

  • Combine flow cytometry, immunohistochemistry, and RNA-seq approaches

  • Include both in vitro (cell line) and in vivo (mouse model) experiments

  • Consider analyzing tumor microenvironment changes using multiparameter flow cytometry or single-cell RNA sequencing

These approaches help distinguish between tumor-cell-intrinsic and -extrinsic roles of IRF1 in antitumor immunity .

What methods are available to study post-translational modifications of IRF1 and how do these modifications affect its function?

Several methodological approaches can be used to study IRF1 post-translational modifications:

• Ubiquitination analysis:

  • Immunoprecipitate IRF1 using specific antibodies

  • Western blot analysis with anti-ubiquitin antibodies

  • Study SPOP-mediated proteasomal degradation of IRF1 through mutational analysis of predicted degron sites

• Phosphorylation studies:

  • Phospho-specific antibodies (when available)

  • Phos-tag™ SDS-PAGE to separate phosphorylated from non-phosphorylated forms

  • Mass spectrometry analysis of immunoprecipitated IRF1

  • Site-directed mutagenesis of potential phosphorylation sites

• SUMOylation detection:

  • Co-immunoprecipitation with SUMO proteins

  • In vitro SUMOylation assays

  • SUMO-site predictive algorithms followed by mutational analysis

• Acetylation analysis:

  • Study KAT8-mediated K78 acetylation of IRF1, which affects its binding to the CD247 (PD-L1) promoter

  • Use acetylation inhibitors and analyze effects on IRF1 function

  • Employ acetyl-lysine specific antibodies for Western blotting

These modifications significantly affect IRF1 function by altering:

• Protein stability and half-life

• DNA binding capacity to target gene promoters

• Protein-protein interactions and complex formation

• Subcellular localization

For example, SPOP-mediated ubiquitination targets IRF1 for proteasomal degradation , while KAT8-mediated acetylation enhances its transcriptional activity at the PD-L1 promoter .

How can I validate the specificity of my IRF1 antibody?

Comprehensive validation of IRF1 antibody specificity requires multiple approaches:

• Positive and negative controls:

  • Positive: IFN-gamma treated cells (HeLa, THP-1, HepG2)

  • Negative: IRF1 knockout cells or tissues

  • siRNA/shRNA knockdown of IRF1 as alternative negative control

• Multiple detection methods:

  • Western blot: Single band at 45-50 kDa

  • Immunofluorescence: Nuclear localization pattern after IFN-gamma treatment

  • Cross-validation with multiple IRF1 antibodies targeting different epitopes

• Peptide competition assay:

  • Pre-incubate antibody with blocking peptide

  • Signal should be significantly reduced or eliminated

• Cross-reactivity testing:

  • Test antibody against related IRF family members

  • Confirm species specificity if using in multiple model organisms

• Application-specific validation:

  • For ChIP experiments: Validate by qPCR of known IRF1 binding sites

  • For flow cytometry: Compare with isotype controls and known positive/negative populations

Why might I observe inconsistent IRF1 antibody staining, and how can I address this issue?

Inconsistent IRF1 antibody staining can stem from multiple factors:

• Biological variables:

  • IRF1 expression is highly inducible and dynamic, fluctuating with stimulation conditions

  • Cell cycle variations (synchronized vs. asynchronous cultures)

  • Heterogeneous cell populations with differential IRF1 expression

• Technical variables and solutions:

  Issue	Potential Solution
  Fixation problems	Optimize fixation time (10-15 minutes); test 4% PFA vs. methanol
  Antigen masking	Try different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)
  Antibody concentration	Titrate antibody; recommended dilutions: 1:20-1:200 for IHC, 1:50-1:500 for IF
  Detection sensitivity	Use signal amplification methods (TSA, polymer-based detection)
  Batch variability	Use consistent lot numbers or validate each new lot

• Protocol standardization:

  • Standardize all protocol steps: fixation, permeabilization, blocking, antibody incubation

  • Implement positive controls in every experiment

  • Consider automated staining platforms for consistency

• Storage and handling:

  • Store antibodies according to manufacturer recommendations (-20°C, avoid freeze-thaw cycles)

  • Prepare working aliquots to minimize freeze-thaw cycles

  • Use proper storage buffer (PBS with 0.02% sodium azide and 50% glycerol pH 7.3)

By systematically addressing these variables, researchers can significantly improve staining consistency and experimental reproducibility.

How can I distinguish between specific and non-specific signals when using IRF1 antibodies?

Distinguishing specific from non-specific IRF1 antibody signals requires multiple analytical approaches:

• Biological validation:

  • Confirm that signal increases with IRF1-inducing treatments (IFN-gamma)

  • Verify signal reduction with IRF1 knockdown/knockout

  • Check appropriate subcellular localization (primarily nuclear upon activation)

• Technical controls:

  • Include isotype controls (same species, isotype, and concentration as primary antibody)

  • Perform secondary-only controls to assess background from secondary antibody

  • Use blocking peptide competition to confirm specificity

• Signal characteristics analysis:

  • Specific IRF1 signal should be:

    • At expected molecular weight (45-50 kDa) in Western blots

    • Predominantly nuclear in immunofluorescence of activated cells

    • Inducible by IFN-gamma treatment

    • Reducible by IRF1 siRNA/shRNA

• Cross-validation strategies:

  • Use multiple IRF1 antibodies targeting different epitopes

  • Compare antibody signal with IRF1 mRNA expression data

  • Verify findings using alternative detection methods

• Advanced validation for challenging applications:

  • For ChIP experiments: Include IgG controls and validate with known target genes

  • For immunoprecipitation: Confirm by mass spectrometry identification

  • For tissue staining: Compare with in situ hybridization patterns

By implementing these rigorous validation approaches, researchers can confidently distinguish specific IRF1 signals from non-specific background, ensuring reliable and reproducible experimental results.

How can IRF1 antibodies be used to study protein-protein interactions in the interferon signaling pathway?

IRF1 antibodies can be employed in multiple advanced techniques to study protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate IRF1 using specific antibodies and identify interacting partners

  • Published applications show successful Co-IP using IRF1 antibodies

  • Can detect interactions with other IRF family members (IRF3) and regulators (PP2A)

• Proximity ligation assay (PLA):

  • Visualize and quantify IRF1 interactions with other proteins at single-molecule resolution

  • Particularly useful for detecting transient or weak interactions

  • Requires antibodies from different host species for target proteins

• Chromatin immunoprecipitation (ChIP):

  • Identify DNA-binding sites of IRF1 and co-binding partners

  • IRF1 antibodies have been validated for ChIP applications

  • Can be combined with sequencing (ChIP-seq) for genome-wide binding profiles

• Biomolecular condensate analysis:

  • Study phase separation of KAT8-IRF1 complexes upon IFNγ stimulation

  • Fluorescently labeled IRF1 antibodies can be used to visualize condensate formation

  • Combines with live-cell imaging techniques to observe dynamics

• Bimolecular fluorescence complementation (BiFC):

  • Detect IRF1 interactions when combined with protein fragment complementation

  • Visualize subcellular localization of interaction complexes

  • Requires IRF1 antibodies for validation of expression levels

These techniques have revealed critical interactions, such as how IRF1 interacts with IRF3 to enhance innate immunity and how KAT8-IRF1 condensates regulate PD-L1 expression .

What are the methodological considerations for studying IRF1's role in cancer immunotherapy resistance?

Studying IRF1's role in cancer immunotherapy resistance requires careful methodological considerations:

• Patient sample analysis:

  • Multiplex immunohistochemistry using IRF1 antibodies (1:20-1:200 dilution)

  • Correlate IRF1 expression with response to immune checkpoint blockade

  • Compare pre- and post-treatment biopsies to assess IRF1 dynamics

• Cancer cell line models:

  • Generate IRF1 knockout or overexpression cancer cell lines

  • Compare response to immunotherapy agents in vitro and in vivo

  • Research has shown IRF1-negative tumors respond better to immune checkpoint blockade

• IRF1-mediated PD-L1 regulation:

  • Study KAT8-IRF1 biomolecular condensate formation using antibody-based detection methods

  • Test peptide inhibitors (like 2142-R8) that disrupt KAT8-IRF1 interaction

  • Quantify changes in PD-L1 expression using flow cytometry and Western blot

• Tumor microenvironment assessment:

  • Use flow cytometry with IRF1 antibodies (0.50 μg per 10^6 cells)

  • Perform spatial transcriptomics to map IRF1 expression patterns

  • Correlate with immune cell infiltration and activation status

• Experimental design considerations:

  • Include appropriate controls (IRF1 WT vs. KO tumors)

  • Use multiple cancer models to validate findings

  • Consider temporal dynamics of IRF1 expression in response to treatment

These methodological approaches help elucidate the dual role of IRF1 in antitumor immunity, where it can have opposing tumor-cell-intrinsic and tumor-cell-extrinsic effects .

How can mass cytometry (CyTOF) be optimized for IRF1 detection in complex immune cell populations?

Optimizing mass cytometry (CyTOF) for IRF1 detection in complex immune populations requires several specific considerations:

• Metal conjugation strategy:

  • Select rare earth metals with minimal signal overlap (e.g., 153Eu, 165Ho)

  • Use commercially available metal-conjugated IRF1 antibodies or custom conjugation

  • Validate conjugated antibodies against unconjugated versions to ensure epitope recognition is maintained

• Panel design considerations:

  • Include IRF1 in transcription factor panels alongside STAT1, STAT3, T-bet, RORγt

  • Plan for metal channel selection to minimize spillover

  • Add surface markers for immune cell identification (CD3, CD4, CD8, CD19, etc.)

• Sample preparation optimization:

  • Fixation: 1.6% PFA for 10 minutes at room temperature

  • Permeabilization: Methanol-based (for nuclear transcription factors like IRF1)

  • Cell concentration: 1-3 million cells per sample

  • Barcoding: Consider using palladium-based barcoding for batch processing

• Antibody titration:

  • Perform careful titration using positive controls (IFN-gamma treated cells)

  • Test range of concentrations (typically 0.25-2 μg per million cells)

  • Evaluate signal-to-noise ratio for optimal concentration determination

• Validation strategies:

  • Use stimulation controls (± IFN-gamma)

  • Include IRF1 knockout or knockdown controls

  • Cross-validate with conventional flow cytometry

  • Confirm specificity with orthogonal measurements (qPCR, Western blot)

• Data analysis approaches:

  • Apply dimensionality reduction (tSNE, UMAP)

  • Implement unsupervised clustering algorithms (FlowSOM, Phenograph)

  • Correlate IRF1 expression with activation markers and cytokine production

  • Consider trajectory analysis to map IRF1 dynamics in responding cells

This optimized CyTOF approach enables single-cell analysis of IRF1 expression patterns across diverse immune populations, revealing how IRF1 regulates different immune cell subsets in various disease contexts.

What emerging applications of IRF1 antibodies show promise for advancing our understanding of immune regulation?

Several emerging applications of IRF1 antibodies show significant promise for advancing immunological research:

• Single-cell multiomics integration:

  • Combining IRF1 antibody-based protein detection with single-cell transcriptomics

  • CITE-seq and REAP-seq approaches to correlate IRF1 protein levels with transcriptional profiles

  • Reveals heterogeneity in IRF1 activity at single-cell resolution

• Spatial biology applications:

  • Multiplexed immunofluorescence using IRF1 antibodies in tissue sections

  • Imaging mass cytometry for high-parameter spatial analysis of IRF1 in the tumor microenvironment

  • Correlating IRF1 expression with spatial location and cellular neighborhoods

• Targeted protein degradation studies:

  • Using IRF1 antibodies to monitor degradation dynamics

  • Studying SPOP-mediated ubiquitination and proteasomal degradation of IRF1

  • Developing and testing proteolysis-targeting chimeras (PROTACs) against IRF1

• Biomolecular condensate research:

  • Investigating phase separation properties of IRF1 with techniques like optoDroplet

  • Monitoring KAT8-IRF1 condensate formation in response to IFNγ stimulation

  • Developing inhibitors of pathological condensate formation

• Intravital imaging approaches:

  • Using fluorescently labeled IRF1 antibody fragments for in vivo imaging

  • Monitoring real-time dynamics of IRF1 expression in disease models

  • Correlating with treatment response in preclinical models

These emerging applications leverage advances in technology to provide deeper insights into how IRF1 orchestrates immune responses in complex biological systems, potentially revealing new therapeutic targets for immune modulation.

How might IRF1 antibodies be utilized in developing new cancer immunotherapy approaches?

IRF1 antibodies can play crucial roles in developing novel cancer immunotherapy approaches:

• Biomarker development:

  • Use IRF1 antibodies to assess IRF1 expression levels in tumor biopsies

  • Stratify patients for immunotherapy based on IRF1 expression patterns

  • Research shows that IRF1-negative tumors may respond better to immune checkpoint blockade

• Therapeutic target identification:

  • Study IRF1-regulated pathways using antibody-based techniques

  • Identify druggable targets in the IRF1 signaling network

  • Focus on the KAT8-IRF1 interaction as a potential therapeutic target

• Combination therapy approaches:

  • Screen for drugs that modulate IRF1 expression or activity

  • Use IRF1 antibodies to monitor treatment effects in preclinical models

  • Develop rational combinations of IRF1-targeting agents with existing immunotherapies

• Engineered cell therapies:

  • Monitor IRF1 expression in engineered T cells or NK cells

  • Optimize IRF1 levels in CAR-T cells to enhance antitumor activity

  • Use antibodies to assess IRF1 status in ex vivo expanded tumor-infiltrating lymphocytes

• Novel therapeutic peptides development:

  • Screen peptides that disrupt pathological IRF1 interactions

  • Use antibodies to validate the mechanism of action of peptides like 2142-R8 that disrupt KAT8-IRF1 condensates

  • Monitor effects on downstream targets like PD-L1

These applications highlight how IRF1 antibodies can bridge basic research with clinical applications, potentially leading to more effective and personalized cancer immunotherapy approaches.

What methodological innovations might improve the specificity and sensitivity of IRF1 detection in complex biological samples?

Several methodological innovations show promise for enhancing IRF1 detection specificity and sensitivity:

• Recombinant antibody technologies:

  • Single-chain variable fragments (scFvs) targeting IRF1-specific epitopes

  • Nanobodies with superior tissue penetration properties

  • Bi-specific antibodies for enhanced specificity through dual epitope recognition

• Proximity-based detection systems:

  • Proximity extension assays (PEA) for ultrasensitive IRF1 detection

  • SplitBioCID or other split protein complementation assays

  • FRET-based antibody pairs for live-cell IRF1 dynamics

• Advanced microscopy techniques:

  • Super-resolution microscopy (STORM, PALM) using IRF1 antibodies

  • Expansion microscopy for improved spatial resolution

  • Lattice light-sheet microscopy for dynamic IRF1 visualization

• Aptamer-based detection:

  • Development of IRF1-specific aptamers as antibody alternatives

  • Aptamer-antibody hybrid detection systems

  • Combining with electrochemical detection for point-of-care applications

• Computational enhancement methods:

  • Machine learning algorithms for signal deconvolution

  • Automated image analysis pipelines for quantifying IRF1 expression patterns

  • Predictive models for IRF1 activity based on multiple parameters

• Multiplexed detection platforms:

  • DNA-barcoded antibody methods for highly multiplexed protein detection

  • Mass spectrometry immunoassays for simultaneous detection of IRF1 and its modified forms

  • Digital spatial profiling for high-plex spatial analysis of IRF1 in tissue context